Kiora Pharmaceuticals Inc (KPRX): Cash & Equivalents
$8.70M
As of 2025-12-31
$7.08M
As of 2026-06-30
+13.4%
3-year compound annual growth
+49.0%
5-year compound annual growth
+0.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.70M | +129.3% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $3.79M | +54.5% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $2.45M | -58.8% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $5.96M | -24.1% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $7.85M | +562.5% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $1.19M | -68.6% | 2022-07-07, Balance as of period end |
| 2019-12-31 | $3.78M | -52.8% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $8.00M | +2.5% | 2020-03-04, Balance as of period end |
| 2017-12-31 | $7.81M | +114.7% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $3.64M | -56.7% | 2018-03-02, Balance as of period end |
| 2015-12-31 | $8.39M | n/m | 2017-02-23, Balance as of period end |
| 2014-12-31 | $167.0K | n/a | 2016-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.70M | +129.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare KPRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗